NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 10 January 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Dr Peter Baker-Gulliver Present for all items
4. Richard Ballerand Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Justin Daniels Present for all items
7. Ana Duarte Present for all items
8. Dr Steve Edwards Present for all items
9. Mohamad Farhat Present for all items
10. Dr Fiona MacPherson Smith Present for all items
11. Professor G.J. Melendez-Torres Items 1 to 4.2.2
12. Dr Pratheeban Nambyiah Present for all items
13. Hugo Pedder Present for all items
14. Becky Pennington Present for all items
15. Dominic Pivonka Present for all items
16. Dr Mohit Sharma Present for all items
17. Alan Thomas Present for all items

NICE staff (key players) present

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Sally Doss, Heath Technology Assessment Adviser Items 1 to 4.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 5 to 5.2.2

Rachel Ramsden, Heath Technology Assessment Analyst Items 1 to 4.2.2

Heather Stegenga, Heath Technology Assessment Analyst Items 5 to 5.2.2

Ruth Melville, Senior Medical Editor Items 1 to 4.2.2

Sarah Bromley, Senior Medical Editor Items 5 to 5.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 5 to 5.1.3

Laura Kelly, Assistant Project Manager Items 5 to 5.2.2

Carl Jackson, Assistant Project Manager Items 5 to 5.2.2

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Marcia Miller, Administrator, TA Present for all items

NICE staff (observers) present

Emily Eaton Turner, Technical Adviser, Commercial Liaison team Present for all items

Sarah Wilkes, Technical Analyst, Commercial Liaison team Present for all items

George Millington, Technical Analyst, Technology Appraisals team Items 1 to 4.2.2

Georgina Fletcher, Media Relations Executive, Media Relations team Items 4.1.3 to 5.2.2

Emma Bajela, Associate HTA Analyst, Scientific Advice team Items 5 to 5.2.2

External assessment group representatives present

Rob Hodgson, Centre for Reviews and Dissemination and Centre for Health Economics -York, Item 4.1.3

Brian O’Toole, Peninsula Technology Assessment Group, University of Exeter (PenTAG), Items 5 to 5.1.3

G.J. Melendez-Torres, Peninsula Technology Assessment Group, University of Exeter (PenTAG), Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all items

Eluned Hughes, Patient expert nominated by Jo’s Cervical Cancer Trust, Items 1 to 4.1.3

Dr Alexandra Taylor, Consultant in Clinical Oncology, clinical expert nominated by Merck Sharp and Dohme, Items 1 to 4.1.3

Dr Susan Lalondrelle, Consultant Clinical Oncologist, clinical expert nominated by NCRI-ACP-RCP-RCR, Items 1 to 4.1.3

Dr Clare Green, Medical Oncologist, clinical expert nominated by Merck Sharp and Dohme, Items 5 to 5.1.3

Helen White, Patient expert nominated by Peaches Womb Cancer Trust, Items 5 to 5.1.3

Grace Remmington, Patient expert nominated by Peaches Womb Cancer Trust, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Radha Todd welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Professor Abdallah Al-Mohammad, Dr Craig Buckley, Dr David Maudgil, Dr Louis Choo and Min Ven Teo.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 13 December 2022.

### Appraisal of Pembrolizumab in combination with platinum-based chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
  + Committee member Becky Pennington declared a financial interest as she has received private consultancy fees from Roche for methodological research into carers' outcomes which is ongoing. This work is not specific to any drug or disease area and is not related to cervical cancer or bevacizumab.. It was agreed that her declaration would not prevent Becky from participating in discussions on this appraisal.
  + Nominated clinical expert Dr Alexandra Taylor declared a direct financial interest, having worked on an MSD advisory board in February 2022. Dr Taylor also declared an indirect financial interest as they have received an education grant in an unrelated area, and a direct non-financial interest due to being a council member for the International Gynae Cancer Society (2020-present), council member and guidelines co-chair for the British Gynaecological Cancer Society. It was agreed that these declarations would not prevent Dr Taylor from providing expert advice to the committee.
  + Nominated clinical expert Dr Susan Lalondrelle declared an indirect non-financial professional and personal interest, due to conducting research on the use of pembrolizumab for other indications. Dr Lalondrelle also declared an indirect financial interest, as they have received educational and travel grants from MSD. It was agreed that these declarations would not prevent Dr Lalondrelle from providing expert advice to the committee.
  + Nominated patient expert Eluned Hughes declared an indirect financial interest, as his organisation has received educational grants from MSD. It was agreed that this declaration would not prevent Eluned from providing expert advice to the committee.
  + No further interests were declared for this appraisal.
    1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10669>

### Appraisal of Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]

* 1. Part 1 – Open session
     1. The chair Dr James Fotheringham welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr James Fotheringham declared a financial interest as he has conducted a scoping review on barriers of digital technologies for dialysis for Baxter Healthcare, all fees were paid to his employer. It was agreed that his declaration would not prevent Dr James Fotheringham from participating in discussions on this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10692>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 7 February 2023 and will start promptly at 09.30.